CNS disorders
| Focus: | CNS disorders |
|---|---|
| Type: | database (supplied by e-mail as setup.exe file) |
| No. of deals: | 206 |
| No. of companies: | 160 |
| Years covered: | 1996 – 2011 |
| Price: | € 800 ex VAT (if applicable) |
| System requirements: | Windows 2000/Windows XP/Windows Vista/7 |
| Publisher: | PharmaPlus Consultancy B.V. |
Are you about to enter deal negotiations for your CNS therapeutic?
Use PharmaDeal Financials CNS to benchmark your next CNS deal
PharmaDeal Financials CNS
- Deal specifics on more than 200 CNS deals
- Deal making trends since 1996
- Deals from both worldwide licensees like GlaxoSmithKline, Roche and regional licensees Meiji Seika and Paladin Labs
- All indications and compound classes including antibodies, GPCR modulators, ion channel modulators, TRPV antagonists and stem cells
- 38% early stage deals
- Upfront payments for phase II/phase III products up to USD 225 million
- Total milestones per product for ion channel modulators from USD 17 to 359 million
- Research funding per year from USD 1.8 to 10 million
Each deal entry is categorized and searchable by licensor, licensee, indication, compound details, compound name, development stage (research-filed), geographical territory, potential deal size, upfront, total milestones-regulatory milestones-sales milestones payments, profit sharing, royalties on sales, research funding, equity and by year of deal establishment or any combination thereof.
Indications (selection)
Addiction, ADHD, alcohol dependence, Amyloid A amyloidosis, Alzheimer’s Disease, anxiety, Charcot-Marie-Tooth disease, cognitive disorders, dementia, depression, epilepsy, Huntington’s disease, impulse control disordes, insomnia, migraine, motion sickness, narcolepsy, neuropathy, obessive compulisve disorders, pain, panic disorders, Parkinson, schizophrenia, traumatic brain injury
Companies included in database
Abbott Laboratories (Solvay Pharmaceuticals), Ablynx , AC Immune, Acadia Pharmaceuticals, Actavis, Actelion, Acura Pharmaceuticals, Addex Pharmaceuticals, Addrenex Pharmaceuticals, Adolor, Affectis Pharmaceuticals, AFFiRis, Aileron Therapeutics, Albany Molecular Research, Alectos Therapeutics, Alexza Pharmaceuticals, Alkermes, Allergan, Allmiral, Alseres Pharmaceuticals (Boston Life Sciences), Amarin Corporation, Amgen, Applied Neurosolutions, Aradigm Corporation, Archemix Corporation (Nitromed), Astellas Pharma (Yamanouchi), AstraZeneca, Bayer (Schering AG), Bial, BioAxone Therapeutic, BioDelivery Sciences International, Biogen Idec, BioLineRx, BioNumerik Pharmaceuticals, BioTie Therapies (Elbion, Synosia Therapeutics), Biovail Corporaiton, Boehringer Ingelheim, BrainCells, Bristol-Myers Squibb, Celera Corporation (Sequana Therapeutics), Celgene Corporation, Cephalon (Anesta, Medeus Pharma), Ceregene, CoCensys, CoMentis, Cortex Pharmaceuticals, Cubist Pharmaceuticals, Cypress Bioscience, Cytos Biotechnology, Daiichi Sankyo (Asubio Pharma Co.), Dainippon Sumitomo Pharma Co. (Sepracor), deCode Genetics, Depomed, Discovery Partners International (Discovery Therapeutics), DOV Pharmaceutical, Durect Corporation, Elan Corporation, Eli Lilly & Company, Endo Pharmaceuticals (Indevus Pharmaceuticals/Interneuron Pharmaceuticals), Envoy Therapeutics, Epix Pharmaceutials, Evotec (Renovis), Fabre Kramer Pharmaceuticals, Forest Laboratories (Clinical Data (Genaissance Pharmaceuticals)), Genmab, GlaxoSmithKline (GlaxoWellcome, SmithKline Beecham), Glenmark Pharmaceuticals, Grünenthal, Guilford Pharmaceuticals, GW Pharmaceuticals, Heptares Therapeutics, Hisamitsu Pharmaceutical Co (Noven Pharmaceuticals), Hydra Biosciences, IDEA, Idera Pharmaceuticals, Impax Laboratories, Ingenium Pharmaceuticals, Innogenetics, Intra-Cellular Therapeutics, Ipsen Pharma, Jazz Pharmaceuticals (Orphan Medical), Johnson & Johnson (Alza, Centocor, Janssen Pharmaceutica), Kissei Pharmaceutical Co., Kowa Company (ProEthic Pharmaceuticals), Kyowa Hakko Kirin Co., Lexicon Pharmaceuticals (Lexicon Genetics), Ligand Pharmaceuticals (Pharmacopeia), Lundbeck, MAP Pharmaceuticals, Marina Biotech (MDRNA/Nastech Pharmaceutical Company), Meda, MEdivation, Meiji Seika Kaisha, Merck & Co (Schering-Plough/Organon, Sibia Neurosciences), Merck Serono (Ares-Serono, Merck KGaA, Serono), Mesoblast, MorphoSys, Mundipharma, Myriad Genetics, Nabi Biopharmaceuticals, NektarThearpeutics, Neurimmune Therapeutics, Neurochem, Neurocrine Biosciences, Neurogen Corporation, NeuroSearch, Newron Pharmaceuticals (Hunter-Fleming), NicOx, Novartis, Omeros Corporation, Orexo (Biolipox), Orion Corporation, Otsuka Pharmaceutical Co., Pain Therapeutics, PAION (CeNeS Pharmaceuticals), Paladin Labs, PanGenetics, Penwest Pharmaceutical Co., Pfizer (Coley Pharmaceuticals, ICAgen, King Pharmaceuticals (Alpharma), Pharmacia Corporation, Warner-Lambert, Wyeth/American Home Products, Wyeth-Ayerst), Pharnext, Phytopharm, Pierre Fabre, Pozen Pharmaceutical Development Company, Proneuron Biotechnologies, ProStrakan Group, Proximagen Neuroscience (Minster Pharmaceuticals), PTC Therapeutics, Purdue Pharma, QRx Pharma, Questor Pharmaceuticals (RiboGene), RaQualia Pharma, reMYND, Roche (Genentech, Memory Pharmaceuticals), Sanofi (Aventis-Pharma, Genzyme Corporation, Rhône-Poulenc Rorer, Sanofi-Aventis), Santhera Pharmaceuticals, Scion Pharmaceuticals, Shionogi (Sciele Pharma), Shire (New River Pharmaceuticals, Roberts Pharmaceutical), SkyePharma, Somaxon Pharmaceuticals, Somnus Therapeutics, Sosei, Suven Life Sciences, Taisho Pharmaceutical Co., Takeda Pharmaceutical Company (Millennium Pharmaceuticals, Nycomed), Targacept, Teva Pharmaceutical Industries, Titan Pharmaceuticals, Torrey Pines Therapeutics (Axonyx), Toyama Chemicals, Transcept Pharmaceuticals, Transition Therapeutics, TransTech Pharma, UCB Pharma (Celltech/Oxford Glycosciences, Schwarz Pharma), Upsher-Smith Laboratories, Valeant Pharmaceuticals, Vernalis (Vanguard Medica), Vertex Pharmaceuticals, Vical, Vitae Pharmaceutials, Voyager Pharmaceutical Corporation, Xcell Pharmaceuticals, Xenon Pharmaceuticals, Xenoport, XTL Biopharmaceuticals, Yoshitomi Pharmaceutical Industries, Zalicus (Neuromed Pharmaceuticals)
